Therapeutic Time Window of Disease‐Modifying Therapy for Early Alzheimer's Disease
Baseline CDR-GS and MMSE emerge as strong predictors of how long individuals remain within the therapeutic time window for early AD DMTs. These findings can guide clinicians in prioritizing patients most at risk of losing eligibility and inform scheduling decisions when faced with extended wait times, ultimately helping to optimize the use of limited healthcare resources.
Authors
- Yoshiki Niimi (ORCID: https://orcid.org/0000-0002-2556-8167)
- Saki Nakashima (ORCID: https://orcid.org/0000-0003-4227-4758)
- Takeshi Iwatsubo
- Tatsushi Toda
- Kenichiro Sato
Institutions
- University of Tokyo Hospital (JP)
- The University of Tokyo (JP)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70860_097785
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00